Research Article
Therapeutic Potential of Novel Twin Compounds Containing Tetramethylpyrazine and Carnitine Substructures in Experimental Ischemic Stroke
Figure 2
Primary time and dose screening of the compound LR134 in experimental ischemic stroke. (a) Neurological deficit scores showing neurobehavioral manifestations in LR134-treated cerebral ischemic rats at different administration times. (b) Representative photographs of 2,3,5-triphenyltetrazolium chloride (TTC) staining in LR134-treated cerebral ischemic rats at different administration times. (c) The cerebral edema index and calculated infarct volume in different groups of rats. versus sham-operated (sham) group, versus ischemia reperfusion- (I/R-) vehicle group ().
(a) |
(b) |
(c) |